NYSE:WST - West Pharmaceutical Services Stock Price, Price Target & More

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services declared a quarterly dividend on Friday, May 4th. Shareholders of record on Wednesday, July 18th will be given a dividend of $0.14 per share on Wednesday, August 1st. This represents a $0.56 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 17th. View West Pharmaceutical Services' Dividend History.

West Pharmaceutical Services declared that its board has initiated a stock buyback program on Thursday, February 15th 2018, which authorizes the company to buyback 800,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its shares are undervalued.

West Pharmaceutical Services Inc. (NYSE:WST) released its quarterly earnings data on Thursday, April, 26th. The medical instruments supplier reported $0.62 EPS for the quarter, missing the Zacks' consensus estimate of $0.64 by $0.02. The medical instruments supplier had revenue of $415.70 million for the quarter, compared to analyst estimates of $403.87 million. West Pharmaceutical Services had a return on equity of 14.40% and a net margin of 8.20%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 earnings per share. View West Pharmaceutical Services' Earnings History.

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for West Pharmaceutical Services.

West Pharmaceutical Services issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $2.80 to $2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.82. The company issued revenue guidance of $1.72 billion to $1.73 billion, compared to the consensus revenue estimate of $1.72 billion.

5 brokerages have issued 1 year price objectives for West Pharmaceutical Services' shares. Their predictions range from $85.00 to $115.00. On average, they anticipate West Pharmaceutical Services' stock price to reach $104.20 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Ratings for West Pharmaceutical Services.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to West Pharmaceutical Services include Eisai (ESALY), OTSUKA HOLDINGS/ADR (OTSKY), Centene (CNC), Amadeus It Group (AMS), McKesson (MCK), Fresenius Medical Care AG & Co. KGaA (FME), Essilor International Cmgn Gnl D Optq (EI), Teva Pharmaceutical Industries (TEVA), Zimmer Biomet (ZBH), TERUMO Corp/ADR (TRUMY), LONZA Grp AG/ADR (LZAGY), IDEXX Laboratories (IDXX), COLOPLAST A/S/ADR (CLPBY), Cerner (CERN) and Sunny Optical Technology (Group) (SNPTF).

Media coverage about WST stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a coverage optimism score of 0.02 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 45.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

West Pharmaceutical Services' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.33%), Riverbridge Partners LLC (0.64%), Retirement Systems of Alabama (0.17%), Nisa Investment Advisors LLC (0.10%), Municipal Employees Retirement System of Michigan (0.02%) and Amalgamated Bank (0.02%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner, Paula A Johnson and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Retirement Systems of Alabama, Fisher Asset Management LLC, Municipal Employees Retirement System of Michigan, Oakbrook Investments LLC, Amalgamated Bank and World Asset Management Inc. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Daniel Malone and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.

WST stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Bank of Montreal Can, Xact Kapitalforvaltning AB and State of Alaska Department of Revenue. View Insider Buying and Selling for West Pharmaceutical Services.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WST stock can currently be purchased for approximately $99.60.

West Pharmaceutical Services has a market capitalization of $7.27 billion and generates $1.60 billion in revenue each year. The medical instruments supplier earns $150.70 million in net income (profit) each year or $2.78 on an earnings per share basis. West Pharmaceutical Services employs 7,500 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]